TICKERNERD
Menu
VORVORHealthcare · Biotechnology

VOR Stock Forecast: Vor Biopharma, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$25
+3.34% on the day

The 9 Wall Street analysts covering Vor Biopharma, Inc. hold a median 12-month price target of $40 — +59.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 5 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.5B
Ticker Nerd rank
15 / 100
Median analyst target
$40
Analysts covering
9
Revenue$0.0
Operating income−$47.9M
Net income−$62.8M
Free cash flow−$25.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+10.6%
1M
+12.6%
YTD
+91.5%
1Y
−35.1%
From 52W high
−48.6%
From 52W low
+265.2%
$7
$49
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VOR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vor Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Sept 2026
15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
84
Value
63
Size
40
Quality
30
Revisions
28
Accruals
19
Momentum
18
Issuance
14
Volatility
9

Growth (84): Sales and profits are climbing, and climbing faster than before.

Volatility (9): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VOR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VOR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26VORHigh $50Median $40Low $27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $27Median $40High $50

The green dot is the last close — the median target sits +59.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026WedbushMaintainsNeutral$18 → $27
18 May 2026HC Wainwright & Co.ReiteratesBuy$31
18 May 2026HC Wainwright & Co.ReiteratesBuy—
14 May 2026WedbushMaintainsNeutral$15 → $18
14 May 2026WedbushMaintainsNeutral—
15 Apr 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026WedbushMaintainsNeutral—
30 Mar 2026JefferiesInitiatesBuy—
19 Mar 2026Wells FargoInitiatesOverweight—
9 Jan 2026CitigroupInitiatesBuy—
19 Dec 2025JP MorganMaintainsOverweight—
17 Dec 2025TD CowenInitiatesBuy—
9 Dec 2025JP MorganInitiatesOverweight—
25 Nov 2025WedbushAssumesNeutral$9.00
14 Nov 2025HC Wainwright & Co.MaintainsBuy—
29 Oct 2025HC Wainwright & Co.MaintainsBuy—
15 Oct 2025BairdUpgradeOutperform—
14 Aug 2025HC Wainwright & Co.ReiteratesBuy—
30 June 2025HC Wainwright & Co.UpgradeBuy—
27 June 2025BairdMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VOR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VOR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Vor Biopharma, Inc. returned −35.1% against +20.0% for the S&P 500, dividends included.

VOR vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26VORS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VOR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Vor Biopharma, Inc. (VOR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
−6.8×

Cheaper than 97% of US stocks

EV / EBITDA
−8.7×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
423.6%

Higher than 99% of US stocks

Return on assets
−21.4%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vor Biopharma, Inc. (VOR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vor Biopharma, Inc. has a market value of $1.5B and an enterprise value of $1.0B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: $627.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$140.8M.

  • Shares outstanding: 54.5M.

  • Trailing P/E: 0.1×; forward P/E: −6.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Vor Biopharma, Inc. employs 76 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

VOR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VORVor Biopharma, Inc.$1.5B
15
ABSIAbsci Corp.$1.5B
34
AKTSAktis Oncology, Inc.$1.5B
1
RAREUltragenyx Pharmaceutical, Inc.$1.5B
44
LTGOLatigo Biotherapeutics, Inc.$1.5B
0
MAZEMaze Therapeutics, Inc.$1.4B
19
BCAXBicara Therapeutics, Inc.$1.5B
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vor Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VOR news & analysis

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 4 Sept 2026neutral

Vor Bio announced that on September 1, 2026, its Compensation Committee granted stock options for 83,600 shares and RSUs for 17,900 shares of common stock to six newly hired employees. The awards were granted as material inducements to employment under the 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — VOR watchers would note that these equity grants signal the hiring of new staff, which can indicate the company is expanding its workforce to support its clinical-stage autoimmune disease programs.

Vor Bio To Participate in Upcoming September Conferences

GlobeNewsWire · 1 Sept 2026neutral

Vor Bio announced that management will participate in several investor conferences in September, including the Wells Fargo 21st Annual Healthcare Conference, Citi's 2026 Biopharma Back to School Conference, Morgan Stanley's 24th Annual Global Healthcare Conference, Baird's 2026 Global Healthcare Conference, and Stifel's Virtual Immunology and Inflammation Forum, featuring fireside chats, presentations, and 1x1 meetings. A live webcast of presentations will be available on the company's investors website.

Why it matters — This announcement indicates Vor Bio's management will be accessible to investors and analysts at multiple upcoming financial conferences, offering opportunities for the company to present updates on its clinical-stage autoimmune disease programs.

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 3 Aug 2026neutral

On August 1, 2026, Vor Bio's Compensation Committee granted stock options to purchase 32,550 shares and RSUs for 6,900 shares of common stock to five newly hired employees. The grants were made as material inducements to employment under Nasdaq Listing Rule 5635(c)(4) and the company's 2023 Inducement Plan.

Why it matters — VOR watchers would note this as a routine disclosure of equity-based compensation tied to new hires, reflecting the company's use of inducement awards to attract talent.

FAQ

Frequently asked questions about VOR stock

What is the VOR stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Vor Biopharma, Inc. have a median 12-month price target of $40, with estimates ranging from $27 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VOR stock a buy right now?

Of the 9 analysts covering Vor Biopharma, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vor Biopharma, Inc. 15 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VOR?

As at 5 Sept 2026, Vor Biopharma, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (84 of 100).

Will VOR stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +59.7% from the last close, and Ticker Nerd's factor model ranks Vor Biopharma, Inc. 15 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VOR stock forecast for 2030?

No analyst covering Vor Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $50 over the next 12 months.

How has VOR stock performed over the past year?

Vor Biopharma, Inc. returned -35.1% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vor Biopharma, Inc. do?

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases.

What is the latest news on VOR?

The most recent item we track (GlobeNewsWire, 4 Sept 2026): "Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)". Vor Bio announced that on September 1, 2026, its Compensation Committee granted stock options for 83,600 shares and RSUs for 17,900 shares of common stock to six newly hired employees. The awards were granted as material inducements to employment under the 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About Vor Biopharma, Inc.

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its lead program is telitacicept, a dual-target fusion protein designed to regulate abnormal B-cell activity that drives autoantibody-mediated conditions. The company’s current development and commercialization efforts center on autoimmune indications such as generalized myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s disease, and IgA nephropathy. Vor Biopharma works on advancing this therapy through clinical development and broader market access, positioning its platform within the specialized immunology and biopharmaceutical segments. Headquartered in Cambridge, Massachusetts, Vor Biopharma plays a role in the market by addressing serious chronic diseases with targeted biologic treatment approaches.

CEO Dr. Jean-Paul Kress M.D. · 76 employees · United States · https://www.vorbio.com